The Asia Pacific Cardiac Marker Testing Market should witness market growth of 9.1% CAGR during the forecast period (2022-2028).
The measurement of cardiac biomarkers can aid in the diagnosis of a disease. Unlike cardiac imaging, which frequently confirms a diagnosis, simpler and less costly cardiac biomarker measures can inform a physician as to whether more complex or invasive procedures are necessary. In many instances, medical societies encourage physicians to use biomarker measurements as an initial screening method, particularly for patients with a low risk of cardiac mortality.
Numerous acute cardiac marker IVD products are designed for unconventional markets, such as hospital emergency rooms, as opposed to traditional hospital or clinical laboratory settings. Intense competition exists in the development and growth of cardiac marker diagnostic products into new markets. Recently, other potential cardiac markers have been identified as a result of the purposeful loss of myocardial via alcohol septal ablation.
Patients with acute myocardial infarction (MI) and those with SCAD are often distinguished by blood levels of cardiac markers of myocardial necrosis. However, circulating indicators of myocyte injury have recently been identified in patients with SCAD and have been proven to have a graded connection with the later risk for cardiovascular mortality as well as heart failure due to more sensitive cardiac troponin assays.
The considerable senior population in the region is one of the major factors driving the Asia Pacific's market expansion. China's elderly population is ageing faster than the rest of the world. The number of people over 65 increased from 42 million in 1953 to 72 million in 1978. Urban areas experience a faster increase in the elderly population than rural ones. China's elderly population is expected to increase to 11% by the end of the century and 20% by 2025.
The China market dominated the Asia Pacific Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $665.8 million by 2028. The Japan market is estimated to grow a CAGR of 8.4% during (2022-2028). Additionally, The India market would experience a CAGR of 9.8% during (2022-2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End-user, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
The measurement of cardiac biomarkers can aid in the diagnosis of a disease. Unlike cardiac imaging, which frequently confirms a diagnosis, simpler and less costly cardiac biomarker measures can inform a physician as to whether more complex or invasive procedures are necessary. In many instances, medical societies encourage physicians to use biomarker measurements as an initial screening method, particularly for patients with a low risk of cardiac mortality.
Numerous acute cardiac marker IVD products are designed for unconventional markets, such as hospital emergency rooms, as opposed to traditional hospital or clinical laboratory settings. Intense competition exists in the development and growth of cardiac marker diagnostic products into new markets. Recently, other potential cardiac markers have been identified as a result of the purposeful loss of myocardial via alcohol septal ablation.
Patients with acute myocardial infarction (MI) and those with SCAD are often distinguished by blood levels of cardiac markers of myocardial necrosis. However, circulating indicators of myocyte injury have recently been identified in patients with SCAD and have been proven to have a graded connection with the later risk for cardiovascular mortality as well as heart failure due to more sensitive cardiac troponin assays.
The considerable senior population in the region is one of the major factors driving the Asia Pacific's market expansion. China's elderly population is ageing faster than the rest of the world. The number of people over 65 increased from 42 million in 1953 to 72 million in 1978. Urban areas experience a faster increase in the elderly population than rural ones. China's elderly population is expected to increase to 11% by the end of the century and 20% by 2025.
The China market dominated the Asia Pacific Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $665.8 million by 2028. The Japan market is estimated to grow a CAGR of 8.4% during (2022-2028). Additionally, The India market would experience a CAGR of 9.8% during (2022-2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End-user, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
Scope of the Study
By Disease
- Myocardial Infarction
- Congestive Heart Failure
- Atherosclerosis
- Acute Coronary Syndrome
- Ischemia
By End-user
- Laboratory Testing Facilities
- Point-of-Care Testing Facilities
- Academic Institutions
By Product
- Reagents & Kits
- Instruments
By Biomarker Type
- Troponin I & T
- Creatine kinase-MB(CK-MB)
- Natriuretic peptide (Bnp Or Nt-Probnp)
- Myoglobin
- High-sensitivity C-reactive protein(hs-CRP)
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG (Siemens AG)
- PerkinElmer, Inc.
- BioMérieux S.A.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Cardiac Marker Testing Market by Disease
Chapter 5. Asia Pacific Cardiac Marker Testing Market by End-user
Chapter 6. Asia Pacific Cardiac Marker Testing Market by Product
Chapter 7. Asia Pacific Cardiac Marker Testing Market by Biomarker Type
Chapter 8. Asia Pacific Cardiac Marker Testing Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG (Siemens AG)
- PerkinElmer, Inc.
- BioMérieux S.A.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
Methodology
LOADING...
